
Interconversion of Carboxylic Acid Derivatives



Gleevec – Novartis (\$4.65 Billion in sales in 2015). A kinase inhibitor that is a first of its kind pill capable of treating certain blood cancers with only limited side effects. It was designed to combat leukemias with the relatively common "Philadelphia chromosome" (BCR-ABL kinase gene fusion)